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ABSTRACT 
Background and aims 
Mucosal healing and histological remission are different targets in patients with 
ulcerative colitis, but both rely on an invasive endoscopic procedure. This study aimed 
to assess faecal calprotectin and neutrophil gelatinase B-associated lipocalin as 
biomarkers for disease activity in asymptomatic ulcerative colitis patients. 
Methods 
This was a multicentric cross-sectional study including 371 patients, who were 
classified according to their endoscopic and histological scores. These results were 
evaluated alongside with the faecal levels of both biomarkers. 
Results 
Macroscopic lesions (i.e., endoscopic Mayo score ≥1) were present in 28% of the 
patients, and 9% had active disease according to UCEIS. Moreover, 21% presented 
histological inflammation according to the Geboes index, whereas 15% and 5% 
presented focal and diffuse basal plasmacytosis, respectively. The faecal levels of 
calprotectin and neutrophil gelatinase B-associated lipocalin were statistically higher for 
patients with endoscopic lesions and histological activity. A receiver operating 
characteristic-based analysis revealed that both biomarkers were able to indicate 
mucosal healing and histological remission with an acceptable probability, and cut-off 
levels of 150-250 μg/g for faecal calprotectin and 12 μg/g for neutrophil gelatinase B-
associated lipocalin were proposed. 
Conclusions 
Faecal calprotectin and neutrophil gelatinase B-associated lipocalin levels are a valuable 
addition to assess disease activity in asymptomatic ulcerative colitis patients. Biological 
levels of the analysed biomarkers below the proposed thresholds can rule out the 
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presence of macroscopic and microscopic lesions with a probability of 75% to 93%. 
However, caution should be applied whenever interpreting positive results, as these 
biomarkers present consistently low positive predictive values. 
 
Key words: ulcerative colitis, faecal markers, endoscopic and histological remission 
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INTRODUCTION 
Ulcerative colitis (UC) is a chronic inflammatory condition of the bowel 
characterized by a relapsing and remitting course
1
. This disease (IBD) causes a 
continuous mucosal inflammation of the colon that can affect the rectum and a variable 
extension of the colon
1
. The characteristic lesions found in the mucosa are intense basal 
plasmacytosis - defined as presence of plasma cells around or below the crypts - an 
increase in the diffuse transmucosal lamina propria cells and a widespread architectural 
distortion of the mucosa or crypts
2
. 
Mucosal healing (MH), routinely assessed by endoscopy, is considered a prognostic 
marker, as it has been described as able to predict disease outcomes such as steroid 
need, hospitalization and colectomy
3-5
. Therefore, MH has emerged as an important 
clinical factor in disease progression, both for Crohn’s disease and UC patients3,4,6,7. 
However, from an histological point of view, recovery is often incomplete and 
microscopic evidence of inflammation persists in 16–100% of the patients with 
endoscopically quiescent colitis
5,8
. In fact, histologic changes tend to lag behind clinical 
response and/or remission after starting UC treatment. This quiescent inflammation puts 
patients at risk of further disease relapses or of developing disease complications
5,8
. On 
the other hand, histological remission was shown to decrease colorectal cancer risk in 
UC
7,9
.  
Many histological indices have been described since the 1950s to assess the 
microscopic activity in UC patients; however, until recently none of them had been 
fully validated. Geboes et al. developed a reproducible six-graded classification system 
that accurately discriminates UC patients according to structural changes and chronic 
and acute inflammatory activity. Currently, the Geboes index (2000) is considered to be 
the best classification system for histological assessment of UC, having a kappa 
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coefficient for inter-observer variation of 0.59–0.7010. Given that histological remission 
is considered to be a different target than the endoscopic MH in UC patients, the 
histological assessment of disease activity has been increasingly used by physicians
11
.  
Faecal calprotectin (FC) is considered to be an excellent marker of intestinal 
inflammation, as it reflects the migration of neutrophils through the inflamed bowel 
wall to the mucosa
2
. Multiple studies have revealed that FC is a precise diagnostic tool - 
distinguishing IBD from non-IBD patients - and FC concentrations seem to correlate 
well with the degree of histological and endoscopic inflammation
12-15
.  
Although not studied as well as FC, neutrophil gelatinase B-associated lipocalin 
(NGAL) has also been addressed as a potential surrogate marker for IBD diagnosis and 
monitoring. In fact, a few recent studies have demonstrated that NGAL is elevated in 
the serum of IBD patients (when compared to healthy controls or IBS patients) and have 
reported different cut-off values to predict histological remission and MH
16-19
. 
Moreover, other studies have demonstrated that faecal NGAL levels are a reliable 
marker of UC activity
20
. 
The primary aim of the present study was the evaluation of the accuracy of FC  
to assess both MH and histological remission in UC patients without clinical symptoms. 
Its primary endpoints were: i) to establish the prevalence of histologic inflammation and 
endoscopic activity in patients with clinically asymptomatic UC; and ii) to evaluate the 
sensitivity, specificity, positive predictive value, negative predictive value and accuracy 
of FC to assess histological and/or endoscopic activity. Additionally, NGAL was 
quantified in a subset of patients and evaluated for the same purpose as FC. 
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MATERIALS AND METHODS  
Patients and Study Design  
This was a nationwide and multicentre study: the patients included had a definitive 
diagnosis of UC, according to ECCO guidelines
2
, and were being followed in 9 
Portuguese IBD specialized centres. The inclusion criteria were: i) UC patients older 
than 18 years old; and ii) absence of symptoms according to the Montreal classification 
and Mayo partial score of <2. The exclusion criteria were the use of topic therapies and 
the presence of clinical symptoms.  
All the patients enrolled in this study did so voluntarily, and signed a written 
informed consent. The study was approved by the ethic committee of all hospitals 
involved and by the Portuguese Data Protection Authority (Comissão Nacional de 
Protecção de Dados). The national coordinator of the Portuguese IBD group (GEDII) 
monitored the study. 
All patients were subjected to blood analysis and collected faeces for the 
evaluation of FC and NGAL. A sigmoidoscopy was performed within 24 hours of 
sample collection and without bowel preparation. During this examination sigmoid and 
rectum biopsies were taken. Endoscopic activity was evaluated by the Ulcerative Colitis 
Endoscopic Index of Severity (UCEIS)
21
 and by the Mayo endoscopic sub-score
22
. 
Patients were considered in remission whenever UCEIS was equal or below 1, whereas 
mucosal healing was defined as a Mayo endoscopic sub-score equal to 0
23
. Finally, 19 
patients who had a FC level above 250 μg/g and a normal endoscopic exam were 
subjected to a complete colonoscopy later on, after signing a new informed consent. 
 
Histological assessment  
 The rectum and sigmoid biopsies (two of each) taken during the sigmoidoscopy 
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were subject to central reading by three independent pathologists blinded regarding 
patients' disease status and endoscopic results. Disagreements between the pathologists 
were resolved by a review using a multiheaded microscope and including a fourth 
pathologist (Karel Geboes) in order to reach a final score. The histological assessment 
was performed using the Geboes index
10
. In this study, histological remission was 
defined as a Geboes index inferior to 3.1. Moreover, the degree of basal plasmacytosis 
was evaluated and classified according to the following scale: 0, absent; 1, focal; 2, 
diffuse
24
. 
 
Faecal calprotectin (FC) and neutrophil gelatinase B-associated lipocalin (NGAL) 
 A single stool sample was collected from each patient and divided into smaller 
sub-samples, on which FC and NGAL were quantified following the specific protocols 
described below. FC was extracted and quantified from the stool samples of 364 and 
371 patients, using the QB and the EliA kits respectively (see below). Stools were kept 
at RT until extraction (within a maximum of 7 days after collection) in accordance with 
manufacturer’s instructions (‘Fecal sample preparation kit’ of Roche Diagnostics, 
Germany). Samples were then stored at − 80°C until the assay was performed. FC 
values were determined from samples using two different assays: Quantum Blue, 
hereafter referred to as QB (Buhlmann) and Automated Fluoroimmunoassay-EliA 
test, hereafter referred to as EliA (Phadia, ThermoFisher), according to the 
manufacturers' instructions. 
 NGAL was extracted and quantified from the stool samples of 260 patients. For 
NGAL measurement, sub-samples were kept at 4°C (for a maximum of 48 hours) until 
shipment to the central laboratory (Department of Pharmacology and Therapeutics, 
Faculty of Medicine of University of Porto, Portugal), where stools were stored at -
 by guest on Septem
ber 25, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
Manuscript Doi : 10.1093/ecco-jcc/jjw170
Ac
ce
pt
ed
 M
an
us
cr
ipt
Page 10 of 38 
80ºC. Faecal NGAL was measured by a quantitative enzyme immunoassay (Faecal 
NGAL [LCN2, Lipocalin-2] ELISA Kit, Epitope Diagnostics, San Diego, USA) 
according to the instructions provided by the manufacturer. 
 
Statistical analysis 
Categorical variables were described through absolute (n) and relative (%) 
frequencies and continuous variables were described as mean and standard deviation, 
median, percentiles, and minimum/ maximum values when appropriate. All the reported 
p values were two-sided, and p values below 0.05 were considered to be statistically 
significant. The ability of FC and NGAL to discriminate UC macroscopic and 
microscopic activity from remission was evaluated by plotting receiver operating 
characteristic (ROC) curves and computing the area under the curve (AUC). All data 
was arranged, processed and analysed with SPSS ® v.20.0 data (Statistical Package for 
Social Sciences). Graphs were designed with Prism 6.  
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RESULTS 
Study population 
This cohort enrolled 371 asymptomatic UC patients that were consecutively 
enrolled in this study, and whose demographic and clinical characteristics are depicted 
in Table 1. The female proportion of the population was 53%, while the patients' 
median (IQR) age was 47 (37-59) years, and the median (IQR) period during which the 
patients had been followed-up at medical care centres was 7 (3-12) years. Regarding 
UC localization, 57% had left-sided colitis and 43% had extensive colitis. A total of 366 
patients were medicated: 91% were on oral 5-ASA (mesalazine), 1% was on steroids, 
30% were on AZT (azathioprine) and 10% were on anti-TNF therapy. Moreover, 77 
patients were dependent on steroids, 15 were steroid-resistant and 21 were intolerant to 
AZT.  
 
UC overall assessment: histological analysis, endoscopic activity and biomarkers' 
levels 
The overall assessment of the UC activity in the patients included in this study is 
shown in the Table 2. Most of the patients were in remission according to the 
endoscopic examination: 91% according to UCEIS and 72% according to Mayo 
endoscopic sub-score. These two approaches to the endoscopic results had an overall 
high correlation (Spearman’s coefficient= 0.894, p<0.001). Moreover, most of the 
patients were also in remission according to the histological examination (79%), and 
basal plasmacytosis was absent in 80% of the patients. The median (IQR) levels of C-
reactive protein (CRP) were 2.0 mg/L (1.0-4.0). Concerning FC levels, 47% to 69% of 
the studied patients were below the pre-established cut-off of 100 μg/g, depending on 
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whether the quantification method was the QB or EliA, respectively. Moreover, the 
median (IQR) values of faecal NGAL were 9.00 μg/g (5.30-18.10). 
 The detailed histological assessment according to the Geboes index is shown in 
Table 3. Despite being clinically asymptomatic, 20% of the patients presented crypt 
involvement, 11.6% presented crypt destruction and 11% presented some degree of 
erosion and ulceration. Fig. 1 illustrates the occurrence of histological inflammation 
stratified according to the Mayo endoscopic sub-score, the UCEIS and the basal 
plasmacytosis grade. As expected, the relative frequency of patients with histological 
inflammation increases with the severity of the other outcomes. Nevertheless, it should 
be noticed that there is a considerable fraction of patients among those whom present no 
endoscopic lesions (10%), an UCEIS below 2 (15%) or no basal plasmacytosis (10%), 
that still have a Geboes index above 3.1 (Fig. 1). The agreement rate between the 
Geboes index and other outcomes used in this study is shown in Table 4: the highest 
accuracy rate (i.e., sum of true positives and true negatives) was found for the UCEIS 
(84%) whereas the accuracy rate concerning the Mayo endoscopic sub-score was 79%. 
Additionally, basal plasmacytosis was significantly associated with the presence 
of endoscopic lesions and histological activity (Supplementary Table 1). In fact, 82% of 
patients without basal plasmacytosis had no endoscopic lesions, while 96% of them 
were in remission according to the UCEIS. Furthermore, 90% of patients without basal 
plasmacytosis had no histological inflammation, and the same percentage of patients 
with diffuse basal plasmacytosis had a Geboes index ≥3.1. 
 
Performance of FC and NGAL levels as UC biomarkers 
The two different methods used to quantify the FC levels in patients' stools (QB 
and EliA) yielded considerably different results. In fact, the FC median (IQR) levels 
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determined by QB were significantly superior to those depicted by EliA (Table 2, 
p<0.001, Wilcoxon test). However, upon categorizing the FC measurements into 
distinct grades, the intraclass correlation coefficient between QB and EliA methods was 
0.710 (95% CI: 0.643-0.764). 
Irrespectively of the method used, the FC levels had a consistent significant 
difference when compared between patients with or without histological and endoscopic 
activity (Fig. 2 and Supplementary Tables 2 and 3). In fact, and as it can be seen in Fig. 
2, FC levels were significantly lower for patients without endoscopic lesions (Mayo 
endoscopic score of 0) when compared to those with lesions, as well as for patients with 
an UCEIS <2. FC levels were also significantly lower for patients in histological 
remission when compared to those with a Geboes index ≥3.1 
The ability of FC levels to assess the presence of macroscopic and microscopic 
lesions in asymptomatic patients was evaluated by plotting a ROC curve for each case 
and computing the respective AUC (Supplementary Fig. 1 and Table 5). The AUC 
values were quite similar between the QB and EliA methods and all of them were 
significant; however, the AUC was smaller for the detection of endoscopic lesions when 
compared to the detection of histological inflammation and disease activity according to 
the UCEIS score. The sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV) and accuracy of the FC levels at different cut-offs to assess 
histological and endoscopic activity are depicted in Table 5. For the same cut-off 
values, the QB method of quantifying FC had a higher sensitivity, whereas the EliA 
method had a higher specificity. The best accuracy ratios were obtained using the EliA 
method with a cut-off of 250 or 300 μg/g: 77%, 70% and 80% for the detection of a 
Geboes index ≥3.1, Mayo endoscopic sub-score ≥1 and UCEIS ≥2, respectively. Even 
though the PPVs were low in this situation (16% to 46%), the NPVs were considerably 
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high and ranged from 74% for the detection of macroscopic lesions to 92% for the 
detection of an UCEIS above or equal to 2. Moreover, a ROC curve was built for the FC 
values considering the presence of either histological or endoscopic remission 
(according to UCEIS or Mayo endoscopic score), and the AUCs are indicated in the 
Supplementary Table 4, as well as the accuracy and related statistics of each cut-off. In 
this scenario, both the FC NPV and accuracy decrease slightly, although the PPV is a 
bit higher, especially when considering the detection of disease activity concerning 
UCEIS. The AUC tends to be lower than that for the detection of each outcome 
individually, with the exception of the detection of endoscopic lesions. 
The presence of NGAL was inspected and quantified in a sub-set of 260 
patients. At this point, it is important to highlight that this sub-set was similar to the left-
out patients regarding the most important disease characteristics and outcomes, and so 
the inclusion of all patients would likely yield similar results (results not shown). Upon 
stratifying NGAL concentrations according to the different analysed outcomes, the 
results have shown that NGAL levels were significantly lower for patients with no 
endoscopic lesions, with an UCEIS <2, or in histological remission, when compared to 
their counterparts (Fig. 3 and Supplementary Table 4). 
The ability of NGAL to assess macroscopic and microscopic lesions was 
evaluated by plotting a ROC for each case and computing the AUCs (Supplementary 
Fig. 1 and Table 6). All AUCs were statistically significant and ranged from 0.635 to 
0.713. The analyses of the NGAL cut-offs for each case are depicted in Table 6: the 
highest accuracy ratio was obtained for a cut-off of 12 μg/g. For the detection of a Mayo 
endoscopic sub-score ≥1, NGAL levels above 12 μg/g had an accuracy of 64% and a 
NPV of 77%; regarding the detection of UCEIS ≥2, the same cut-off had an accuracy 
ratio of 64% and an NPV of 93%; finally, for the detection of a Geboes index ≥3.1 the 
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ratio was 62% and the NPV was 83%. As with the FC, the PPVs regarding NGAL cut-
offs were considerably low (between 15% to 43%). Moreover, a ROC curve was built to 
evaluate the performance of NGAL in the detection of either histological or endoscopic 
remission (according to UCEIS or Mayo endoscopic score). AUC, accuracy and related 
statistics are indicated in the Supplementary Table 4: when compared against their 
counterparts in the specific analysis of each outcome, both accuracy and PPV tend to be 
higher, whereas NPV tends to be lower. The AUC is generally lower than that for the 
detection of each outcome individually. 
The AUCs of the ROC curves using the CRP for the detection of the outcomes 
mentioned above were also computed (Supplementary Fig. 1). However, the AUC was 
in all cases non-significant and below those of the faecal markers. 
Cut-off values of 150 μg/g for the EliA method, 250 μg/g for the QB method and 
12 μg/g for NGAL were chosen as the ones presenting a better balance between 
sensitivity, specificity, PPV and NPV. The overall accuracy and kappa index for FC and 
NGAL using these thresholds are depicted in Table 4, and are below those observed for 
UCEIS and Mayo endoscopic sub-score. Interestingly, both biomarkers were correlated 
with the CRP levels in a weak although significant fashion (Spearman correlation 
coefficients: 0.160, p=0.002 [for FC measured with QB], 0.135, p=0.010 [for FC 
measured with EliA], and 0.195, p=0.002 [for NGAL]). Moreover, NGAL was 
correlated with FC irrespective of the extraction method used (Spearman correlation 
coefficients: 0.544, p<0.001 [for FC measured with QB], 0.597, p<0.001 [for FC 
measured with EliA]). 
Combining the two studied biomarkers – FC and NGAL – seems like a rational 
approach to increase their detection potential. However, such combination did not seem 
to yield better results than the utilization of each marker alone (Supplementary Table 6). 
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In fact, although there is an increase in the accuracy (mostly due to an increase in 
specificity), this difference does not seem to hold any significance on the daily clinical 
practice, as NPVs remained fairly unchanged. 
 
Sigmoidoscopy vs. colonoscopy 
To further explore the relation between FC levels and macroscopic lesions, 
patients that had FC levels above 250 μg/g and a normal sigmoidoscopy were invited to 
do a complete colonoscopy a few months after (data not shown). Nineteen patients have 
accepted to do so, and interestingly, in 16 of those patients macroscopic lesions were 
detected in or above the sigmoid colon, and in 12 of those 16 there was also an increase 
in the Geboes index. 
The choice of a sigmoidoscopy as the patients’ initial endoscopic examination 
instead of a colonoscopy had the rational of avoiding mechanical bowel preparation, 
known to cause structural changes and inflammation, and therefore prone to cause some 
bias in the results
25,26
. Nonetheless, a sigmoidoscopy is unable to detect lesions above 
the lower third of the colon, and therefore one could raise the question whether a more 
complete examination would change the results. In order to address that issue, patients 
were stratified according to their disease location – left-side or extensive colitis. These 
groups were individually analysed regarding FC and NGAL cut-offs (Supplementary 
Tables 7 and 8), and the results show that the 95% CI for sensitivity, specificity, PPV, 
NPV and accuracy are, in the vast majority of cases, overlapping between them.   
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DISCUSSION 
 The gold standard to monitor disease activity in UC patients still includes a 
colonoscopy, usually followed by the histological analysis of sampled biopsies. 
However, colonoscopies are invasive and time-consuming procedures, are relatively 
expensive and cause discomfort to the patients. For these reasons, the optimization and 
validation of biomarkers that can accurately diagnose or monitor disease progression in 
UC (and other IBD) patients is highly desirable. Among the many biomarkers that have 
been explored in this context, FC - a calcium-binding protein that composes up to 60% 
of the neutrophils' cytosol - stands out as a particularly promising one. The presence of 
calprotectin in faeces reflects the leakage of neutrophils into the bowel lumen, usually 
caused by an inflammatory process that alters the mucosal architecture. Hence, FC is 
expected to mirror the integrity of the bowel mucosa. 
 Many studies have been made in the last two decades to measure the ability of 
FC to diagnose and monitor disease activity in IBD patients
27-29
. However, the vast 
majority of these studies focus on the performance of FC to discriminate IBD patients 
from healthy volunteers or patients with irritable bowel syndrome (IBS), or to predict 
disease activity in IBD patients. This study has the particularity of focusing in 
asymptomatic UC patients (N=371), reporting the ability of FC to assess endoscopic 
and histological activity in patients that have a definitive diagnosis but no clinical 
activity of the disease. Additionally, the faecal NGAL levels were also accounted for in 
this context (in 260 patients of this cohort). 
As expected - given the absence of symptoms - most patients were in mucosal 
healing according to the Mayo endoscopic sub-score (72%), in remission according to 
the UCEIS (91%), or had no microscopic signs of inflammation (Geboes <3.1) (79%). 
However, the agreement between these different evaluations was only moderate (79% 
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to 84%). In fact, there are a number of patients with a Geboes index above 3.1 that were 
considered to be in remission according to the Mayo endoscopic sub-score and the 
UCEIS, and that had no basal plasmacytosis. Additionally, 15% of the patients with 
diffuse basal plasmacytosis were considered to be in MH (Mayo endoscopic sub-
score=0), whereas 50% had a UCEIS <2. These results support the previously published 
notion that endoscopic findings fail to indicate the presence of microscopic activity and 
basal plasmacytosis, particularly in mild UC cases
24,30
. Histological remission is a 
clinically relevant end-point that must be taken into consideration, as histological 
inflammation may be a better predictor of clinical relapses than endoscopic lesions in 
UC
5
. Moreover, and in the particular case of patients in clinical remission, the histology 
grade has the strongest association with the risk of clinical relapse
31
. 
 The current literature concerning the utility of FC as an IBD biomarker agrees 
on its potential, but strongly disagrees on the cut-off values proposed - in fact, one can 
easily find variable FC cut-offs within the same context and for the same purpose
28,29
. 
This is likely to be in part due to the variety of commercial kits currently available to 
quantify FC, which are based on a similar method (ELISA) but may differ in specific 
details (e.g., monoclonal vs. polyclonal antibodies). To tackle this issue, two different 
FC quantification kits were used in this study: the QB and the EliA. And whereas the 
results had a high intraclass correlation index, they were rather distant in terms of 
average and median values. Furthermore, the stratification of patients according to the 
pre-established cut-off of 100 μg/g yielded different-sized groups for each of the two 
methods. Notwithstanding, and despite the absolute levels quantified, QB and EliA had 
a similar variation with the different grades of histological activity and endoscopic 
lesions in UC asymptomatic patients. So, different cut-offs have to be optimized and 
validated for each kit and within each context. 
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 Overall, the ROC analysis of the FC levels revealed that FC is a good predictor 
of macroscopic and microscopic activity in asymptomatic UC patients. As cut-off 
values, and considering the best balance between specificity, sensitivity, PPV, NPV and 
accuracy, one should consider 150 μg/g for the EliA method, and 250 μg/g for the QB 
method. Given the low prevalence of inflammatory activity in the asymptomatic 
patients, these cut-off values present considerably high NPVs. So, negative test results 
can exclude the presence of endoscopic activity and microscopic inflammation with an 
appreciable degree of certainty, which can spare the patient from an unnecessary 
colonoscopy. On the other hand, the PPVs tend to be low and never reach 50%. For that 
reason, a positive result (i.e., a test result above the proposed thresholds) must be 
interpreted with caution, and should not be used as the sole basis to justify a complete 
colonoscopy. Such invasive procedure should only be carried out in the presence of 
other indicators (high levels of serum markers or exacerbation of clinical symptoms, for 
instance). 
 Interestingly, Guardiola et al.
32
 have recently proposed that an FC concentration 
lower than 155 μg/g can indicate the absence of acute inflammatory infiltrate with a 
NPV of 89% in UC patients considered to be in clinical and endoscopic remission. Our 
study validates and expands this previous report, using a much larger cohort (371 vs. 
59), a validated histological index, and including the UCEIS and the basal 
plasmacytosis assessment.  
 Additionally, two other studies have reported the potential of FC to predict 
mucosal healing and/or disease flares in patients with quiescent UC
33,34
. However, these 
studies have not included the histological assessment of the patients. Given the 
importance of the histological remission as a primary end-point in UC, particularly in 
the case of patients considered to be in clinical remission
5,31
, we believe that our study 
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offers a more inclusive approach of the FC usefulness in asymptomatic patients. 
Moreover, in one of those studies
33
, the FC cut-off proposed (50 to 13.9 μg/g) was 
much lower then the ones we report here. Whereas the use of topical medication in 15% 
of the patients included in that study may have contributed to the different values 
obtained, the use of a different commercial kit to quantify the FC is likely the reason for 
the generally lower FC levels reported, consequently resulting in a lower cut-off. This 
reinforces the idea postulated earlier that each kit requires a specific optimization and 
validation of the cut-off(s). 
 As a secondary outcome of this study, the potential of faecal NGAL to assess 
mucosal healing and histological remission was evaluated in 260 patients. The AUCs of 
the NGAL levels computed for the Geboes index, the Mayo endoscopic sub-score and 
the UCEIS were significant and ranged from 0.653 to 0.713. The accuracy ratios were 
lower than those obtained for FC. Still, a cut-off of 12 μg/g can be useful in the 
assessment of disease activity. Whereas the number of false positives is rather high, the 
number of false negatives is very low, and therefore a test result below 12 μg/g can 
exclude the presence of histological activity with a probability of 83%, the presence of 
endoscopic lesions with a probability of 77%, and an UCEIS equal to or above 2 with a 
probability of 93%. 
Combining the two biomarkers did not increase the accuracy of the test. Such a 
result is not unexpected: in fact, as the source of calprotectin and NGAL is the same – 
the neutrophils – both biomarkers are expected to reflect the leakage of these cells into 
the lumen, and therefore they should be redundant. Moreover, the AUCs for the CRP 
assessment of endoscopic and histological outcomes were non-significant and below 
those of FC and NGAL, suggesting that faecal markers are likely a better approach to 
detect active disease at least in asymptomatic UC patients. Nevertheless, the 
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combination of FC and/or NGAL with biomarkers of a different nature merits further 
attention in the future. 
The utilization of a sigmoidoscopy as the initial patient’s examination could be 
considered a limitation, as lesions above the lower third of the colon could not be 
detected. However, a sigmoidoscopy avoids bowel preparation, which could affect the 
colon inflammation. Moreover, the 95% CI intervals for sensitivity, specificity, PPV, 
NPV and accuracy regarding FC and NGAL cut-offs are, in the vast majority of cases, 
overlapping for patients with left-side or extensive colitis. This demonstrates that the 
presence of lesions undetected in the sigmoidoscopy do not affect the overall results, 
and therefore the examination performed was adequate and sufficient for this study. 
 The main strengths of this study are the considerable large size of the cohort, the 
collection of stool samples for FC and NGAL analysis in a period of 24 hours prior to 
the sigmoidoscopy, the use of two different assays to quantify the FC, the use of a well-
known and strong index for the histological assessment (Geboes index), and the fact 
that the biopsies were analysed by independent pathologists blinded to the disease 
status. The more recent validated histological indices were indeed not yet published 
when this study was designed
35,36
. As for limitations, one should account for the fact 
that FC quantification was based on a single sample, when De Vos et al. have recently 
shown that two consecutive measurements of calprotectin are more specific than a 
single one for the prediction of relapses
37
. Moreover, this was a cross-sectional study, 
and therefore the progression of the disease - along with that of the FC and NGAL 
levels - was not accounted for. 
 In conclusion, this study reports the presence of histological inflammation and 
even macroscopic lesions among asymptomatic UC patients, and points out that FC and 
faecal NGAL levels can be useful to dismiss the presence of histological and 
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endoscopic activity, therefore reducing the number of unnecessary colonoscopies. FC 
and NGAL are, therefore, clinically relevant biomarkers, as they can aid the physician 
in the follow-up assessment of UC patients without clear symptoms. Their utility to 
predict the presence of lesions is, however, limited, and their utilization for this purpose 
must be complemented by other markers. Moreover, further studies are needed to 
validate the proposed cut-off values, as well as to complement them with a follow-up 
approach, in order to determine whether these (or other) values could also be useful for 
the anticipation and prevention of flares.  
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FIGURE LEGENDS 
Fig. 1. Histological inflammation stratified according to Mayo endoscopic sub-score, 
UCEIS and basal plasmacytosis. 
 
Fig. 2. Minimum to maximum Box and Whiskers plots representing the FC levels 
stratified by different histological and clinical outcomes: A, Mayo endoscopic sub-score 
(0 vs. ≥1); B, UCEIS (<2 vs. ≥2); and C, Geboes index (<3.1 vs. ≥3.1). 
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Fig. 3. Minimum to maximum Box and Whiskers plots representing the NGAL levels 
stratified by different histological and clinical outcomes: A, Mayo endoscopic sub-score 
(0 vs. ≥1); B, UCEIS (<2 vs. ≥2); and C, Geboes index (<3.1 vs. ≥3.1).  
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Table 1 – Characteristics of the population enrolled in the study  
N 371 
Median age (IQR, years) 47 (37-59) 
Gender 
Male, n (%) 174 (47) 
Female, n (%) 197 (53) 
Median time of follow-up, years (IQR, years) 7 (3-12)  
Localization (n=369) 
Left side colitis, n (%) 
Extensive colitis, n (%) 
 
211 (57%) 
158 (43%) 
Smoking habits (n=353) 
Smoker, n (%) 
Ex-Smoker, n (%) 
Non-Smoker, n (%)   
 
20 (6%) 
103 (29%) 
230 (65%) 
Steroid use, n (%) 
Steroid-dependence (n=329) 
Steroid-resistance (n=324) 
 
77 (23%) 
15 (5%) 
AZT intolerant (n=312), n (%) 21 (7%) 
Medication at the time of the study 
Steroid use (n=366) 
AZT, (n=365) 
Anti-TNF, (n=366) 
Oral 5-ASA (n=365) 
 
4 (1%) 
109 (30%) 
37 (10%) 
333 (91%) 
Extra-intestinal manifestations (n=366), n (%) 
 Arthralgia  
 Arthritis 
 Erythema nodosum 
 Uveitis  
74 (20%) 
64 (17%) 
12 (3%) 
6 (2%) 
4 (1%) 
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Table 2 – Characteristics of the population enrolled considering the biomarkers 
measurements, endoscopic and histological activity  
Mayo Endoscopic Score (n=370)  
0: Normal or inactive disease  265 (72%) 
1: Mild disease (erythema, decreased vascular patter, mild 
friability) 
90 (24%) 
2: Moderate 14 (4%) 
3: Severe 
1 (0.3%) 
UCEIS (n=371)  
Remission (0 or 1) 336 (91%) 
Active disease (≥2) 35 (9%) 
Histology (n=370)  
<3.1 291 (79%)  
≥3.1 79 (21%) 
Basal plasmacytosis (n=363)  
0 (absent) 289 (80%) 
1 (focal) 54 (15%) 
2 (diffuse) 20 (5%) 
C-reactive protein, Median (IQR) (n=364) 2.0 (1.0-4.0) mg/L 
NGAL, Median (IQR) (n=260) 9.00 (5.30-18.10) μg/g 
FC (QB) Median (IQR) (n=364) 114.00 (41.00-310.00) μg/g 
<100  μg/g 172 (47%) 
≥100  μg/g 192 (53%) 
FC (EliA) Median (IQR) (n=371) 36.40 (9.10-149.00) μg/g 
<100  μg/g 255 (69%) 
≥100  μg/g 116 (31%) 
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Table 3 – Histological classification according to the Geboes index  
 n  (%) 
Grade 0   
0.0 - No abnormality 218 (58.8%) 
0.1 - Mild abdnormality 96 (25.9%) 
0.2 - Mild or moderate diffuse or multifocal abdormalities 52 (14.0%) 
0.3 - Severe diffuse or multifocal abnormalities 5 (1.3%) 
Grade 1 – Chronic inflammatory infiltrate   
1.0 - No increase 92 (24.8%) 
1.1 - Mild but unequivocal increase  199 (53.6%) 
1.2 - Moderate increase 55 (14.8%) 
1.3 - Marked increase 25 (6.7%) 
Grade 2 - Neutrophils and eosinophils in lamina propria   
2A- eosinophils   
2A.0 - No increase 193 (52.0%) 
2A.1 - Mild but unequivocal increase  125 (33.7%) 
2A.2 - Moderate increase 46 (12.4%) 
2A.3 - Marked increase 7 (1.9%) 
2B - Neutrophils   
2B.0 - None 308 (83.0%) 
2B.1 - Mild but unequivocal increase  43 (11.6%) 
2B.2 - Moderate increase 17 (4.6%) 
2B.3 - Marked increase 3 (0.8%) 
Grade 3 - Neutrophils in epithelium   
3.0 - None 297 (80.1%) 
3.1 - < 5% crypts involved 34 (9.2%) 
3.2 - < 50% crypts involved 29 (7.8%) 
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3.3 - > 50% crypts involved 11 (3.0%) 
Grade 4 – Crypt destruction   
4.0 - None 328 (88.4%) 
4.1 - Probable – local excess of neutrophils in part of crypt 26 (7.0%) 
4.2 - Probable –marked attenuation 7 (1.9%) 
4.3 - Unequivocal crypt destruction 10 (2.7%) 
Grade 5 – Erosion or ulceration   
5.0 - No erosion, ulceration, or granulation tissue 330 (88.9%) 
5.1 - Recovering epithelium+adjacent inflammation 8 (2.2%) 
5.2 - Probable erosion - focally stripped 12 (3.2%) 
5.3 - Unequivocal erosion 15 (4.0%) 
5.4 - Ulcer or granulation tissue 6 (1.6%) 
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Table 4 – Comparison between the histological score and the other outcomes  
 
  
 Accuracy (%) Kappa (95% CI) 
Mayo endoscopic sub-score (0 vs. ≥1) 79% 0.429 [0.325;0.533] 
UCEIS (<2 vs. ≥2) 84% 0.394 [0.276;0.512] 
FC - QB (<250 vs. ≥250 μg/g) 70% 0.200 [0.092;0.308] 
FC - EliA (<150 vs. ≥150 μg/g) 75% 0.283 [0.171;0.395] 
NGAL (<12 vs. ≥12 μg/g ) 62% 0.130 [0.014;0.245] 
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Table 5: Assessment of UC outcomes by FC  
Assessment of endoscopic lesions (Mayo endoscopic sub-score ≥1) 
AUC (QB)= 0.590 (95% CI: 0.524 -0.657), p=0.008 
AUC (EliA)= 0.635 (95% CI: 0.570-0.699), p<0.001 
[QB/EliA] μg/g Sen (%) Spe (%) PPV (%) NPV (%) Accuracy(%) 
QB/EliA ≥ 50  77/59 32/63 31/39 79/79 45/62 
QB/EliA ≥ 100 61/47 51/75 33/42 77/78 54/67 
QB/EliA ≥ 150 55/37 62/80 35/42 78/76 60/68 
QB/EliA ≥ 200 45/32 67/83 34/44 76/76 61/69 
QB/EliA ≥ 250 37/28 74/86 36/44 75/75 64/70 
QB/EliA ≥ 300 36/23 78/88 39/43 76/74 66/69 
Assessment of activity (UCEIS ≥2) 
AUC (QB)= 0.701 (95% CI: 0.607-0. 795), p=0.001 
AUC (EliA)= 0.717 (95% CI: 0.627-0.807), p<0.001 
QB/EliA ≥ 50  88/71 32/59 12/15 96/95 37/60 
QB/EliA ≥ 100 77/54 50/71 14/16 95/94 52/70 
QB/EliA ≥ 150 74/43 60/77 16/16 96/93 61/74 
QB/EliA ≥ 200 65/34 67/80 17/15 95/92 67/76 
QB/EliA ≥ 250 44/31 73/84 14/17 93/92 70/79 
QB/EliA ≥ 300 41/26 76/86 15/16 93/92 73/80 
Assessment of histological activity 
AUC (QB)= 0.732 (95% CI: 0.674-0.791), p<0.001 
AUC (EliA)=0.735 (95% CI: 0.676-0.795), p<0.001 
QB/EliA ≥ 50  92/67 36/63 28/33 94/88 48/63 
QB/EliA ≥ 100 81/57 55/76 33/39 91/87  60/72 
QB/EliA ≥ 150 74/48 65/82 37/42 90/85  67/75 
QB/EliA ≥ 200 62/42 71/85 37/43 87/84 69/76 
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QB/EliA ≥ 250 46/38 76/88 35/46 84/84 70/77 
QB/EliA ≥ 300 44/32 79/89 37/45 84/83 72/77 
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Table 6: Assessment of UC outcomes by NGAL  
 
Assessment of endoscopic lesions (Mayo endoscopic sub-score ≥1) 
AUC= 0.653 (95% CI: 0.583-0.723), p<0.001 
[NGAL] μg/g Sen (%) Spe (%) PPV (%) NPV (%) Accuracy(%) 
Ngal≥7 77 40 36 80 52 
Ngal≥10 62 62 42 79 62 
Ngal≥12 53 69 43 77 64 
Assessment of activity (UCEIS ≥2) 
AUC= 0.713 (95% CI: 0.618-0. 809), p<0.001 
Ngal≥7 93 38 15 98 44 
Ngal≥10 67 58 15 94 58 
Ngal≥12 59 64 16 93 64 
Assessment of histological activity 
AUC= 0.689 (95% CI: 0.616-0.763), p<0.001 
Ngal≥7 84 40 28 90 50 
Ngal≥10 60 59 29 84 59 
Ngal≥12 51 66 29 83 62 
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Figure 1 
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Figure 2 
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Figure 3 
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